Full-Time

Director Site Quality

Updated on 8/1/2026

Indivior

Indivior

501-1,000 employees

Pharma: treats addiction and mental illness

Compensation Overview

$200k - $230k/yr

+ Bonus + Long-Term Incentive Plan grant + 401(k) company match + Profit-Sharing Plan + Employee Stock Purchase Plan

Raleigh, NC, USA

In Person

Category
Biology & Biotech (1)
Required Skills
GMP
FDA Regulations
Quality Assurance (QA)
Microbiology
OSHA

Get referred to Indivior

See people who can refer or advise you

Requirements
  • A Bachelor of Science degree in a life science or engineering discipline is required.
  • Proven direct leadership experience within the pharmaceutical, biopharmaceutical, or biologics industries, with emphasis on sterile drug product manufacture and testing, is required.
  • A successful history with Health Authority inspections and follow-up is required.
  • Thorough understanding of regulatory requirements for testing, manufacturing, and packaging drug products, devices, or combination products is required, including products manufactured for the United States, European Union, and Asia.
  • Clear understanding of cGxP requirements and the ability to assess and act upon product safety, quality, efficacy, and compliance risks for drug and combination products, including product quality complaints, is required.
  • Comprehensive understanding of pharmaceutical and Quality Management processes, test method verifications and validations, and manufacturing and packaging facility requirements is required.
  • Practical application of drug and combination product regulatory requirements is required, including EU GMP, WHO, PIC/S, 21 CFR Parts 210/211, 21 CFR Part 4, and 21 CFR Part 820; Clinical Trial Regulations including ICH E6, E2A, E8, and 21 CFR Part 50; and GLP Regulations including Directive 2004/9/EC and 21 CFR Part 58.
  • Experience hosting Competent Authority inspections and communicating with Competent Authority inspectors and officials is required.
  • Strong analytical and problem-solving ability is required.
  • Experience managing controlled substances is required.
  • Strong interpersonal skills and the ability to communicate clearly to all levels of the business through concise written or oral summaries to senior management are required.
  • Influencing skills in areas without direct reporting authority are required.
  • Strong planning and organization skills are required.
  • Proficiency in English is required.
Responsibilities
  • As a member of the Quality Leadership Team, Raleigh Leadership Team, and Site Quality Management Representative, manage and escalate quality and compliance issues to the VP, Quality Management, Director, Quality Operations, and Raleigh Site Director as applicable.
  • Exercise site decision authority to independently halt operations, reject product, and escalate compliance risks.
  • Develop the site quality strategy to ensure continued release of compliant product in a streamlined manner and maintain product availability without disruption.
  • Attract, develop, and lead the site Quality functions, including Quality Assurance and Quality Control.
  • Provide strategic and tactical site-level oversight for quality operations.
  • Assign clear roles and responsibilities in the Quality department to ensure coverage of all fields of responsibility.
  • Provide quality oversight for Quality Assurance, Quality Control, microbiology, aseptic processing, validation, contamination control, training, and site quality systems.
  • Ensure site processes comply with current good manufacturing practices and establish systems that identify process-improvement opportunities.
  • Develop knowledge of and understand regulatory requirements including 21 CFR Parts 210 and 211, current good manufacturing practices, FDA requirements, OSHA requirements, and other regulatory-agency requirements applicable to the Quality role.
  • Provide input into the Indivior Pharmaceutical Quality System to reduce identified risks.
  • Ensure cGxP and process training is conducted for applicable site associates.
  • Establish and measure or report on the effectiveness of the Quality Management System.
  • Independently and objectively report on the site's product quality and compliance state of control.
  • Establish procedures and specifications for adequate manufacturing control.
  • Ensure the site maintains a compliant document-management process for cGMP documents and records.
  • Manage the performance of laboratory tests and examinations according to established methods and specifications.
  • Ensure investigations of nonconformances are conducted appropriately and include root cause analysis.
  • Approve or reject components, active pharmaceutical ingredients, raw materials, and intermediates.
  • Disposition product for release to customers.
  • Provide quality oversight and ensure compliance for external suppliers, providing feedback to the Indivior Audit team.
  • Serve as the primary contact for regulatory authorities regarding site inspections, compliance questions, and ongoing communication.
  • Interact with relevant functions to ensure appropriate systems are maintained and implemented for cGMP compliance.
  • Ensure processes and products comply with all applicable local, state, federal, and international rules and regulations.
  • Identify opportunities for continuous improvement to strengthen quality.
  • Conduct periodic reviews of policies and procedures to strengthen the Pharmaceutical Quality System and meet current company and regulatory requirements.
  • In collaboration with the Indivior Quality Audit function, ensure approval of contractors responsible for raw materials, active pharmaceutical ingredients, manufacture, packaging, testing, distribution, and cGxP-critical services.
  • Manage internal and external documentation flow for Quality Assurance activities, including change management, deviations, laboratory investigations, and nonconformances.
  • Ensure quality incidents are fully investigated, root cause analyses are defined, and corrective and preventive actions are implemented and monitored for effectiveness.
  • Ensure Quality Management Reviews are conducted periodically and report quality performance using key performance indicators that measure Quality Management System and regulatory compliance and drive improvement.
  • In collaboration with Quality Validation and Quality Operations, participate in technology-transfer activities into commercial supply as required.
  • Manage cGxP-critical events and recalls or mock recalls according to procedure.
  • Manage stability studies as applicable.
Desired Qualifications
  • A postgraduate degree is preferred.
  • Prior experience managing contract and/or outsourced organizations is advantageous.
  • Experience in production operations is a plus.
  • Auditing qualifications are advantageous.
  • Fluency in languages other than English is advantageous.

Indivior focuses on developing medicines for substance use disorders and serious mental illnesses. Its products are prescription pharmaceutical treatments, brought to market after research and development, and sold through healthcare professionals to patients worldwide. The company’s approach centers on patient safety, with ongoing monitoring and reporting of adverse events to ensure high-quality therapies. Compared with competitors, Indivior emphasizes targeted medicines for addiction and mental health, combining scientific R&D with a global commercialization presence to address critical healthcare needs. Its goal is to create sustainable value by improving patient outcomes and addressing unmet medical needs in global health.

Company Size

501-1,000

Company Stage

IPO

Headquarters

Bon Air, Virginia

Founded

2014

Get referred to Indivior

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sublocade drove Q1 revenue growth, rising 32% to $232 million.[13]
  • Indivior raised 2026 guidance after Q1 adjusted EBITDA jumped 112% year over year.[13]
  • INDV-2000 and INDV-6001 add pipeline optionality in OUD treatment.[10][14]

What critics are saying

  • Revenue depends heavily on U.S. Sublocade performance and payer durability.[13]
  • Generic buprenorphine competition continues pressuring Suboxone and Subutex pricing.[11][3]
  • Opioid-liability litigation can disrupt cash flow and capital allocation quickly.[11]

What makes Indivior unique

  • Indivior is the market leader in long-acting injectable OUD medicines.[4]
  • Sublocade anchors a differentiated monthly buprenorphine platform for opioid dependence.[3][5]
  • Perseris extends the portfolio into schizophrenia and serious mental illness.[5][9]

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid Vacation

Paid Holidays

Paid Sick Leave

Flexible Work Hours

Remote Work Options

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Adoption Assistance

Tuition Reimbursement

Employee Stock Purchase Plan

401(k) Company Match

Profit Sharing

Legal Services

Pet Insurance

Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

0%
Indivior
Mar 17th, 2026
National survey finds only 58% of U.S. Correctional facilities offer medications for opioid use disorder.

National survey finds only 58% of U.S. Correctional facilities offer medications for opioid use disorder. * Jails outpace prisons in offering MOUD, but regional disparities and limited treatment access persist across the U.S. * Qualitative feedback points to need for greater reentry support, housing, care coordination, and provider training RICHMOND, Va., March 17, 2026 (GLOBE NEWSWIRE) - Indivior Pharmaceuticals Inc. (Nasdaq: INDV) announced results from a cross-sectional survey published in the Journal of Correctional Health Care that reveal critical gaps in the availability of medications for opioid use disorder (MOUD) across U.S. correctional facilities. Funded by Indivior and conducted in partnership with the National Commission on Correctional Health Care (NCCHC), the study surveyed 212 jails, prisons, and detention centers. Findings indicate that just 58% offer at least one FDA-approved MOUD and stark disparities in treatment access exist across regions and facility types. The study found that jails were more than twice as likely to provide MOUD compared to prisons and that facilities in the West had over three-fold higher odds of offering MOUD than those in the Midwest. Regional disparities persist, with facilities in the South, Midwest and rural areas reporting the greatest uncertainty about care delivery. Despite increasing awareness of the benefits of MOUD, the South reports the lowest rates of treatment access, with fewer than 10% of diagnosed individuals receiving treatment. Midwest facilities report moderate levels of treatment for diagnosed individuals, some below 10%, while others report between 20%-29%. "This study reinforces the urgent need to integrate evidence-based care into jails and prisons," said Christian Heidbreder, PhD, Chief Scientific Officer at Indivior. "To truly address the opioid crisis, we must ensure continuity of care, expand access to medications for opioid use disorder, and eliminate the stigma that prevents people from receiving treatment during and after incarceration." Correctional settings are among the most critical intervention points for opioid use disorder (OUD) treatment: An estimated 17% of individuals in state prisons and 19% of those in jails meet the criteria for OUD.1 Research shows that individuals in their first two weeks post-release from incarceration face overdose mortality rates that are up to 40 times higher than the national average.2 MOUD treatment during incarceration can significantly reduce these risks and improve treatment retention.3 "With renewed national attention on strengthening addiction treatment and recovery, our study underscores both the opportunities and the challenges ahead," said Vanessa Procter, Executive Vice President, Corporate Affairs at Indivior. "We're encouraged to see recovery rising on the federal agenda, and these data offer a roadmap for expanding life-saving care inside jails and prisons. Improving continuity of care - from incarceration to community - is not a partisan issue. It's a public health imperative, and the evidence shows what works." In addition to quantitative findings, the survey captured qualitative insights from correctional health professionals on ideal infrastructure to support reentry and reduce reincarceration. Respondents identified five critical areas for improving MOUD continuity and outcomes: * Access to long-acting injectables and telehealth: Respondents called for greater investment in cost-effective medications, including funding for injectable treatments like extended-release buprenorphine and extended-release naltrexone, as well as telemedicine partnerships to extend care into rural settings. * Continuity of care and transition services: Respondents emphasized the importance of pre-release planning and providing a warm handoff from incarceration to community-based MOUD services. * Housing and employment: Respondents highlighted the role of transitional housing, job training, and financial stability in sustaining recovery. * Comprehensive MOUD treatment approaches: Respondents advocated for "medical homes" that combine MOUD with mental health care, infectious disease treatment, and social support. * Community support networks: Respondents pointed to the value of peer mentorship, recovery organizations, and community-based programs to promote engagement post-release and reduce re-incarceration. Despite growing recognition of MOUD as the standard of care for OUD, many facilities cited persistent barriers to implementation, including stigma, abstinence-only philosophies, lack of provider training, limited budgets, and geographic disparities in healthcare infrastructure. About Indivior. As the leader in long-acting injectable treatments for opioid use disorder (OUD), Indivior is singularly focused on delivering evidence-based treatment and advancing understanding of OUD as a chronic but treatable brain disease. For more than 25 years, Indivior PLC has revolutionized the science of addiction medicine - developing treatments that help people move toward long-term recovery with independence and dignity. Building on this heritage, Indivior PLC is ushering in a new era, renewing its commitment to individuals living with OUD and carrying forward what matters most: compassion, integrity, and science. Together - with science, people living with OUD, public health champions, and communities, Indivior PLC is powering recovery and renewing hope. Visit www.indivior.com to learn more. Connect with Indivior on LinkedIn by visiting www.linkedin.com/company/Indivior. Investors Enquiries: Jason Thompson VP, Investor Relations Indivior +1 804 402 7123 [email protected]

StreetInsider
Mar 13th, 2026
Indivior prices $450M convertible notes offering to repay debt and buy back shares

Indivior Pharmaceuticals has priced a $450 million convertible senior notes offering due 2031, up from the initially announced $400 million. The company also granted purchasers a 30-day option to buy an additional $50 million in notes. The notes carry a 0.625% annual interest rate and an initial conversion rate of 24.0033 shares per $1,000 principal amount, representing a conversion price of approximately $41.66 per share — a 35% premium over the 12 March closing price. The notes mature on 15 March 2031. Indivior will use approximately $239 million of proceeds, plus $102 million cash on hand, to repay borrowings and terminate its credit facilities. Another $75 million will fund share repurchases of roughly 2.4 million shares. The sale is expected to settle on 17 March 2026.

Yahoo Finance
Feb 26th, 2026
Indivior hits $856M SUBLOCADE revenue in 2025, eyes faster growth in 2026

Indivior reported record SUBLOCADE net revenue of $856 million in 2025, contributing to total net revenue of $1.24 billion. The company described 2025 as a "transition year" whilst completing phase one of its Indivior Action Agenda focused on maximising business performance and expanding treatment for opioid use disorder. CEO Joe Ciaffoni highlighted the elimination of a $295 million Department of Justice liability. The company reported adjusted EBITDA of $428 million with improved margins, whilst reducing operating expenses to $622 million year-over-year. Commercial momentum strengthened in the fourth quarter, with new patient starts reaching record weekly highs and active prescribers hitting all-time levels. The Move Forward in Recovery direct-to-consumer campaign, launched in October 2025, drove a 15% increase in branded search volume and significantly boosted treatment provider tool usage.

Yahoo Finance
Feb 26th, 2026
Indivior reports record $252M quarterly SUBLOCADE revenue, launches $400M share buyback

Indivior Pharmaceuticals has reported record financial results for 2025, with full-year SUBLOCADE net revenue reaching $856 million, up 13% year-over-year. Fourth quarter SUBLOCADE revenue totalled $252 million, up 30% versus the prior year quarter. The company achieved full-year adjusted EBITDA of record levels, growing 20% year-over-year. The company completed Phase I of its Action Agenda in December 2025 and has entered Phase II, focused on acceleration. Indivior expects mid-teens SUBLOCADE dispense unit growth in 2026, with operating expenses capped at $450 million and approximately $300 million in cash flow from operations. The company has authorised a new $400 million share repurchase program with an 18-month term and completed its redomiciliation from the UK to the US in January 2026.

PR Newswire
Jul 8th, 2025
Indivior Appoints Vanessa Procter as Executive Vice President of Corporate Affairs

RICHMOND, Va., July 8, 2025 /PRNewswire/ - Indivior PLC (Nasdaq / LSE: INDV) today announced the appointment of Vanessa Procter as Executive Vice President of Corporate Affairs, effective July 7, 2025.